Immunotherapy before surgery boosts survival for for liver cancer patients, clinical research finds

Immune checkpoint inhibitor (ICI) therapy before surgery for hepatocellular carcinoma (HCC) may produce major pathological response in about one-third of the surgical patients. The clinical and pre-clinical research highlighted that the formation of organized immune hubs within the tumor (tertiary lymphoid structure) after ICI therapy is critical for the induction of antitumor immunity.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup